Additive effect of probiotics (Mutaflor) on 5-aminosalicylic acid therapy in patients with ulcerative colitis

Additive effect of probiotics (Mutaflor) on 5-aminosalicylic acid therapy in patients with ulcerative colitis

Background/Aims In ulcerative colitis (UC) patients, Escherichia coli Nissle 1917 (EcN) is equivalent to mesalazine for preventing disease relapse; however, evidence of the ability of EcN to increase health-related quality of life or induce remission remains scarce. We investigated the efficacy of E...

Full description

Bibliographic Details
Main Authors:	Soo-Kyung Park, Sang-Bum Kang, SangSoo Kim, Tae Oh Kim, Jae Myung Cha, Jong Pil Im, Chang Hwan Choi, Eun Soo Kim, Geom Seog Seo, Chang Soo Eun, Dong Soo Han, Dong Il Park
Format:	Article
Language:	English
Published:	The Korean Association of Internal Medicine 2022-09-01
Series:	The Korean Journal of Internal Medicine
Subjects:	escherichia coli nissle 1917 colitis ulcerative quality of life
Online Access:	http://kjim.org/upload/pdf/kjim-2021-458.pdf

Similar Items

Adherence to Asacol once daily versus divided regimen for maintenance therapy in ulcerative colitis: a prospective, multicenter, randomized study
by: Soo-Kyung Park, et al.
Published: (2019-07-01)

Quorum sensing in the probiotic bacterium <it>Escherichia coli</it> Nissle 1917 (Mutaflor) – evidence that furanosyl borate diester (AI-2) is influencing the cytokine expression in the DSS colitis mouse model
by: Jacobi Christoph A, et al.
Published: (2012-08-01)

Transcriptional Profiling of the Probiotic <i>Escherichia coli</i> Nissle 1917 Strain under Simulated Microgravity
by: Jaewoo Yim, et al.
Published: (2020-04-01)

Probiyotik Escherichia coli Suşu Nissle 1917
by: Seda Altuntaş, et al.
Published: (2017-12-01)

Probiyotik Escherichia coli Suşu Nissle 1917
by: Seda ALTUNTAŞ, et al.
Published: (2017-12-01)

Efficacy of sigmoidoscopy for evaluating disease activity in patients with ulcerative colitis
by: Su Bum Park, et al.
Published: (2022-02-01)

5-Aminosalicylic Acid-induced Myocarditis in a Patient with Atypical Ulcerative Colitis
by: Hyo Yeop Song, et al.
Published: (2022-01-01)

Probiyotik Escherichia coli Suşu Nissle 1917
by: Seda Altuntaş, et al.
Published: (2017-12-01)

Probiyotik Escherichia coli Suşu Nissle 1917
by: Seda Altuntaş, et al.
Published: (2017-12-01)

Inhibitory Effect of E. coli Nissle 1917 on Clinical and Standard Strains of Pseudomonas aeruginosa
by: Sheyda Damoogh, et al.
Published: (2021-01-01)

Is infection a real threat in patients with ulcerative colitis? A prospective, multicenter study in Korea
by: Dae Bum Kim, et al.
Published: (2018-04-01)

Clinical and Immunological Aspects of Probiotic Therapy for Chronic HP-Associated Gastritis in Children
by: O.Ye. Abaturov, et al.
Published: (2013-11-01)

Substantial Extracellular Metabolic Differences Found Between Phylogenetically Closely Related Probiotic and Pathogenic Strains of Escherichia coli
by: Justin J. J. van der Hooft, et al.
Published: (2019-02-01)

Activation of immune and defense responses in the intestinal mucosa by outer membrane vesicles of commensal and probiotic Escherichia coli strains
by: Maria José eFábrega, et al.
Published: (2016-05-01)

Engineered 5-HT producing gut probiotic improves gastrointestinal motility and behavior disorder
by: Bei Li, et al.
Published: (2022-10-01)

A Machine Learning-Based Diagnostic Model for Crohn’s Disease and Ulcerative Colitis Utilizing Fecal Microbiome Analysis
by: Hyeonwoo Kim, et al.
Published: (2023-12-01)

Probiotic Escherichia coli Nissle 1917-derived outer membrane vesicles modulate the intestinal microbiome and host gut-liver metabolome in obese and diabetic mice
by: Jun Shi, et al.
Published: (2023-08-01)

pMPES: A Modular Peptide Expression System for the Delivery of Antimicrobial Peptides to the Site of Gastrointestinal Infections Using Probiotics
by: Kathryn Geldart, et al.
Published: (2016-10-01)

In Vitro Evaluation of the Impact of the Probiotic E. coli Nissle 1917 on Campylobacter jejuni’s Invasion and Intracellular Survival in Human Colonic Cells
by: Yosra A. Helmy, et al.
Published: (2017-08-01)

Wild-type Escherichia coli Nissle 1917 improves hyperuricemia by anaerobically degrading uric acid and maintaining gut microbiota profile of mice
by: Yanmei Sun, et al.
Published: (2024-01-01)

A comparative study on the genomes, transcriptomes, and metabolic properties of Escherichia coli strains Nissle 1917, BL21(DE3), and MG1655
by: Linlin Zhao, et al.
Published: (2022-03-01)

Anti-cancer properties of Escherichia coli Nissle 1917 against HT-29 colon cancer cells through regulation of Bax/Bcl-xL and AKT/PTEN signaling pathways
by: Siamak Alizadeh, et al.
Published: (2020-07-01)

Antibacterial Effects of Compound Bifilact on E.coli and Campylobacter jejuni
by: Hamidreza Ebrahimnezhad, et al.
Published: (2020-01-01)

Production of Reactive Oxygen (ROS) and Nitrogen (RNS) Species in Macrophages J774A.1 Activated by the Interaction between Two <i>Escherichia coli</i> Pathotypes and Two Probiotic Commercial Strains
by: Berenice González-Magallanes, et al.
Published: (2023-06-01)

Long-term outcomes of infliximab in a real-world multicenter cohort of patients with acute severe ulcerative colitis
by: Shin Ju Oh, et al.
Published: (2021-07-01)

Development of a Genome-Scale Metabolic Model and Phenome Analysis of the Probiotic <i>Escherichia coli</i> Strain Nissle 1917
by: Dohyeon Kim, et al.
Published: (2021-02-01)

Comprehensive probiogenomics analysis of the commensal Escherichia coli CEC15 as a potential probiotic strain
by: Tales Fernando da Silva, et al.
Published: (2023-11-01)

Second Korean guidelines for the management of ulcerative colitis
by: Chang Hwan Choi, et al.
Published: (2017-01-01)

Assessment of the Safety and Efficacy of an Oral Probiotic-Based Vaccine Against Aspergillus Infection in Captive-Bred Humboldt Penguins (Spheniscus humboldti)
by: Milan Thorel, et al.
Published: (2022-05-01)

The Uncertain Effect of Antimicrobial Therapy in the Treatment of Patients with Ischemic Colitis
by: Jae Gon Lee, et al.
Published: (2020-07-01)

Metabolomics Study on Pathogenic and Non-pathogenic <i>E. coli</i> with Closely Related Genomes with a Focus on Yersiniabactin and Its Known and Novel Derivatives
by: Mareike Schulz, et al.
Published: (2020-05-01)

Advances in Escherichia coli Nissle 1917 as a customizable drug delivery system for disease treatment and diagnosis strategies
by: Haojie Chen, et al.
Published: (2023-02-01)

Engineered Escherichia coli Nissle 1917 with urate oxidase and an oxygen-recycling system for hyperuricemia treatment
by: Rui Zhao, et al.
Published: (2022-12-01)

Production and Sensing of Butyrate in a Probiotic <i>E. coli</i> Strain
by: Yanfen Bai, et al.
Published: (2020-05-01)

Novel Genetically Engineered Probiotics for Targeted Elimination of <i>Pseudomonas aeruginosa</i> in Intestinal Colonization
by: Hyun Kim, et al.
Published: (2023-09-01)

Patient Preference and Adherence to Aminosalicylates for the Treatment of Ulcerative Colitis
by: Tripathi K, et al.
Published: (2021-08-01)

K5 Capsule and Lipopolysaccharide Are Important in Resistance to T4 Phage Attack in Probiotic E. coli Strain Nissle 1917
by: Manonmani Soundararajan, et al.
Published: (2019-11-01)

Intestinal probiotics E. coli Nissle 1917 as a targeted vehicle for delivery of p53 and Tum-5 to solid tumors for cancer therapy
by: Lian He, et al.
Published: (2019-06-01)

Development of a Machine Learning Model to Distinguish between Ulcerative Colitis and Crohn’s Disease Using RNA Sequencing Data
by: Soo-Kyung Park, et al.
Published: (2021-12-01)

Clinical importance of weight gain and associated factors in patients with moderate to severe ulcerative colitis: results from the MOSAIK cohort in Korea
by: Hyuk Yoon, et al.
Published: (2023-11-01)